


WHAT IS CLAIMED IS:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

- 10 A is O or S;

X is a bond or CH<sub>2</sub>;

- 15 R<sup>1</sup> is selected from the group consisting of H and C<sub>1</sub>-C<sub>3</sub> alkyl, wherein C<sub>1</sub>-C<sub>3</sub> alkyl is optionally substituted with 1-3 F;

Each R<sup>2</sup> is independently selected from the group consisting of F, Cl, CH<sub>3</sub>, CF<sub>3</sub>, -OCH<sub>3</sub>, and -OCF<sub>3</sub>;

- 20 Each R<sup>4</sup> is independently selected from the group consisting of halogen, C<sub>1</sub>-C<sub>3</sub> alkyl, -OC<sub>1</sub>-C<sub>3</sub> alkyl, -OC(=O)C<sub>1</sub>-C<sub>3</sub> alkyl, and -S(O)<sub>q</sub>C<sub>1</sub>-C<sub>3</sub> alkyl, wherein C<sub>1</sub>-C<sub>3</sub> alkyl, -OC<sub>1</sub>-C<sub>3</sub> alkyl, -OC(=O)C<sub>1</sub>-C<sub>3</sub> alkyl, and -S(O)<sub>q</sub>C<sub>1</sub>-C<sub>3</sub> alkyl are optionally substituted with 1-3 F;

Each R<sup>5</sup> is independently selected from the group consisting of F, Cl, CH<sub>3</sub>, -OCH<sub>3</sub>, CF<sub>3</sub>, and -OCF<sub>3</sub>;

- 25 R<sub>6</sub> is selected from the group consisting of C<sub>2</sub>-C<sub>5</sub> alkyl, -CH<sub>2</sub>Cyclopropyl, and -C(=O)C<sub>1</sub>-C<sub>3</sub> alkyl, wherein said R<sub>6</sub> substituent is optionally substituted with 1-3 F;

m is 0 or 1;

n is an integer from 1-3;

- 30 p is an integer from 0-2; and

q is an integer from 0-2.

2. The compound according to Claim 1, wherein  $R^1$  is H or  $CH_3$ .

5 3. The compound according to Claim 1, wherein  $R^1$  is  $CH_3$ .

4. The compound according to Claim 1, wherein A is O.

10 5. The compound according to Claim 1, wherein each  $R^4$  is independently selected from the group consisting of F, Cl,  $CH_3$ ,  $CF_3$ ,  $-OCH_3$ ,  $-OCF_3$ ,  $-OCHF_2$ ,  $-OC_2H_5$ ,  $-OC(=O)CH_3$ , and  $-S(O)_qCH_3$ , wherein q is 0, 1 or 2, and n is 1 or 2.

6. The compound according to Claim 1, wherein X is a bond.

15 7. The compound according to Claim 1, wherein X is  $CH_2$ .

8. The compound according to Claim 1, wherein  $R^6$  is selected from the group consisting of  $n-C_3H_7$ ,  $-CH_2Cyclopropyl$ , and  $-C(=O)C_2H_5$ .

20 9. The compound according to Claim 1, wherein  $R^6$  is  $n-C_3H_7$ .

10. The compound according to Claim 1, wherein p is 0 or 1.

11. The compound according to Claim 1, wherein

25  $R^1$  is H or  $CH_3$ ;

Each  $R^4$  is independently selected from the group consisting of F, Cl,  $CH_3$ ,  $CF_3$ ,  $-OCH_3$ ,  $-OCF_3$ ,  $-OCH_2CH_3$ ,  $-OC(=O)CH_3$ ,  $-OCHF_2$ , and  $-S(O)_qCH_3$ ,

30  $R_5$  is Cl or F;

$R_6$  is selected from the group consisting of  $n-C_3H_7$ ,  $-CH_2Cyclopropyl$ , and  $-C(=O)C_2H_5$ ;

35 m is 0;

n is 1 or 2;  
p is 0 or 1; and  
q is an integer from 0-2.

5                    12.      The compound according to Claim 1, wherein

A is O;

R<sup>1</sup> is CH<sub>3</sub>;

10

Each R<sup>4</sup> is independently selected from the group consisting of Cl, -OCH<sub>3</sub>, -OCF<sub>3</sub>, and -S(O)<sub>2</sub>CH<sub>3</sub>;

R<sup>5</sup> is F;

15      R<sub>6</sub> is n-C<sub>3</sub>H<sub>7</sub>;

m is 0;

n is 1 or 2; and


p is 0 or 1.

20


13.      A pharmaceutical composition comprising a compound of Claim 1, or a  
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A compound of Claim 1, selected from the compounds listed below, or a pharmaceutically acceptable salt thereof:


1




2




3




4




5




6




7




8



9



10



15. The use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Type 2 diabetes mellitus.

5

16. A pharmaceutical composition comprising  
(1) a compound of Claim 1 or a pharmaceutically acceptable salt thereof;  
(2) one or more compounds selected from the group consisting of :

10

- (a) PPAR gamma agonists and partial agonists;
- (b) biguanides;
- (c) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
- (d) dipeptidyl peptidase IV (DP-IV) inhibitors;
- (e) insulin or an insulin mimetic;
- (f) sulfonylureas;

15

(g)  $\alpha$ -glucosidase inhibitors;  
(h) agents which improve a patient's lipid profile, said agents being selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) bile acid sequestrants, (iii) nicotinic alcohol, nicotinic acid or a salt thereof, (iv) PPAR $\alpha$  agonists, (v) cholesterol absorption inhibitors, (h) acyl CoA:cholesterol acyltransferase (ACAT) inhibitors, (i) CETP inhibitors, and (j) phenolic anti-oxidants;

20

- (i) PPAR $\alpha/\gamma$  dual agonists,
- (j) PPAR $\delta$  agonists,
- (k) antiobesity compounds,
- (l) ileal bile acid transporter inhibitors;
- (m) anti-inflammatory agents;
- (n) glucagon receptor antagonists;
- (o) GLP-1;
- (p) GIP-1; and
- (q) GLP-1 analogs; and

25

30 (3) a pharmaceutically acceptable carrier.